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Background and Aim. Pancreatic cancer is one of the most lethal human cancers. High frequency of lymph 
node (LN) metastasis is one of the reasons for this dismal prognosis. Metastasis in LNs along the superior 
mesenteric artery (SMA-LNs) is sometimes found in patients with pancreatic head cancer. Although LNs 
around the right side of the SMA should be dissected as a standard lymphadenectomy during 
pancreatectomy for pancreatic head cancer, the left side of SMA-LNs (SMA-LNs-lt) is out of the range for 
standard lymphadenectomy and not commonly dissected during pancreatectomy for pancreatic head 
cancer. Therefore, studies focused on SMA-LN-lt metastasis in pancreatic cancer rarely performed and 
survival benefit of SMA-LN-lt dissection is still unclear. In addition, the frequency of SMA-LN-lt 
micrometastasis and its prognostic value in patients with pancreatic head cancer have never been 
reported. The current study aimed to investigate the frequency of SMA-LN-lt metastasis detected by 
hematoxylin and eosin (HE) staining and micrometastasis detected by immunohistochemical staining and 
evaluate its prognostic significance of SMA-LN-lt metastasis and micrometastasis in patients who 
received potentially curative resection for pancreatic head cancer. 
 
Materials and Methods. Medical records of consecutive patients with pancreatic head cancer who 
underwent pancreatectomy with curative intent at the Department of Surgery, Hiroshima University 
Hospital, Hiroshima, Japan, between May 2002 and November 2017, were reviewed retrospectively. All 
patients underwent R0 or R1 resection and had confirmed pathological diagnosis of pancreatic ductal 
adenocarcinoma. During this study period, adjuvant gemcitabine plus S-1 (GS) chemotherapy was 
administrated to these patients.  
All the LNs included in the standard lymphadenectomy indicated by the International Study Group on 
Pancreatic Surgery (ISGPS) were dissected. With regard to SMA-LNs, circumferential dissection 
including not only along the right side but also the left side of the SMA was performed. Dissected 
SMA-LNs-lt were removed from pancreatoduodenal specimen and sent for permanent histological 
examination separately. In contrast, the SMA plexus was completely preserved to prevent postsurgical 
diarrhea and associated weight loss. resection of the pancreas was performed. All resected LN specimens 
were cut into complete serial 2-mm slices along the longest axis, and the slices were formalin-fixed, 
paraffin-embedded, and stained with HE staining. SMA-LN-lt micrometastasis was investigated by 
immunohistochemistry with anti-cytokeratin (CAM 5.2) in the SMA-LN-lt sections diagnosed as absent of 
metastasis by HE staining. Survival analyses on clinicopathological factors were performed with 
univariate and multivariate methods.  
 
Results. A total of 389 consecutive patients with pancreatic cancer underwent surgical resection (R0 or R1 
resection) between May 2002 and November 2017. Of these 389 patients, 257 patients received 
pancreatectomy for pancreatic head cancer. Of these 257 patients, separated SMA-LNs-lt were available 
in 166 patients and the other 91 patients whose SMA-LN-lt specimens were not clearly confirmed as 
SMA-LNs-lt were excluded. These 166 patients included 78 males and 88 females with the mean age of 69 
years (range: 37-91). According to the National Comprehensive Cancer Network preoperative resectability 
definition, 92 patients (55%) had resectable (R) and 74 patients (45%) had borderline resectable (BR) 
pancreatic cancer. 29 patients (17%) received neoadjuvant chemotherapy. Sixteen patients (10%) 
experienced postoperative complications. 121 patients (73%) had positive LNs. The median number of 
harvested and metastatic LNs was 27 (range: 3-66) and 2 (range: 0-17), respectively. Adjuvant GS 
chemotherapy was administrated to 137 patients (78%). Among the enrolled 166 patients, 20 patients 
(12%) had SMA-LN-lt metastasis detected by HE (SMA-LN-lt HE-positive). Of the remaining 146 patients 
with SMA-LN-lt HE-negative, 8 patients (5%) had SMA-LN-lt micrometastasis detected by CAM 5.2 
including 2 with single type and 6 with cluster type. Based on SMA-LN-lt status, patients with pancreatic 
head cancer were classified into three groups: SMA-LN-lt no metastasis (n=138), HE-positive (n=20) and 
micrometastasis (n=8). In comparisons of SMA-LN-lt status with clinicopathological factors, resectability 
status (p=.016), LN metastasis (p<.001), R factor (p=.012), and UICC pStage (p<.001) were significantly 
associated with the SMA-LN-lt status.  
In overall survival (OS) analysis, no significant difference was found between patients with SMA-LN-lt 
HE-positive and micrometastasis group with MST of 13.1 and 19.1 months, respectively (p=.861). When 
SMA-LN-lt HE-positive and micrometastasis groups were united, SMA-LN-lt HE-positive or 
micrometastasis group experienced significantly shorter OS than SMA-LN-lt no metastasis group with 
MST of 14.1 and 31.3 months, respectively (p=.015). In 123 patients with LN metastasis or SMA-LN-lt 
micrometastasis, however, no significant difference in OS was found between SMA-LN-lt no metastasis 
and HE-positive or micrometastasis groups (p=.197). Univariate OS analysis demonstrated that 
preoperative resectability status (p=.001), surgical procedure (p=.003), PV/SMV resection (p<.001), 
histologic grade (p=.026), LN metastasis (p<.001), SMA-LN-lt 3 status (p=.046), SMA-LN-lt 2 status 
(p=.015), R factor (p=.012), UICC pT factor (p=.005), UICC pStage (p<.001) and adjuvant GS 
chemotherapy (p<.001) were significantly associated with OS. A multivariate analysis identified PV/SMV 
resection (hazard ratio [HR] 2.19, 95% confidence interval [95% CI] 1.34-3.62, p=.002), higher histologic 
grade (Grade 1 vs 2/3) (HR 1.69, 95% CI 1.01-2.91, p=.046), LN metastasis (HR 2.64, 95% CI 1.39-5.43, 
p=.002), SMA-LN-lt HE-positive or micrometastasis (HR 1.82, 95% CI 1.05-3.05, p=.034) and lack of 
adjuvant chemotherapy (HR 2.63, 95% CI 1.59-4.32, p<.001) as independent risk factors for poor OS. 
Within a subset of 28 patients with SMA-LN-lt HE-positive or micrometastasis, univariate OS analysis 
demonstrated that age (p=.023), histologic grade (p=.003) and adjuvant GS chemotherapy (p<.001) were 
significantly associated with OS. In addition, the MSTs of patients with adjuvant GS chemotherapy in R 
and BR group were 39.5 and 24.3 months, respectively. In multivariate analysis, lack of adjuvant GS 
chemotherapy (HR 4.37, 95% CI 1.65-12.4, p=.003) was the independent prognostic factors for poor OS.  
 
Conclusions. SMA-LN-lt HE-positive and micrometastasis was found in 12% and 5% of eligible patients, 
respectively. SMA-LN-lt HE-positive or micrometastasis was the independent risk factor for poor 
prognosis in patients who received potentially curative pancreatectomy for pancreatic head cancer. 
Adjuvant chemotherapy may contribute to improvement of prognosis in patients with LN metastasis 
including SMA-LN-lt metastasis and micrometastasis. 
